A Phase 3 interventional study of 18F-DCFPyL and PET/CT Imaging in Prostate Cancer, Prostate Adenocarcinoma and Prostate Cancer Recurrent, sponsored by Progenics Pharmaceuticals, Inc.. Completed at 14 sites in 2 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-06-14.
Sponsored by Progenics Pharmaceuticals, Inc. (part of Lantheus Holdings, Inc.) · Phase 3, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 24 studies testing piflufolastat in Prostatic Neoplasms — 5 open to participants now, 10 under way, none of them phase 3. piflufolastat · Prostatic Neoplasms.
Among the 24 studies testing piflufolastat in Prostatic Neoplasms, this one is the 5th largest by enrollment, is one of 4 that started in 2018, is the only one in phase 3, and was the 9th registered.
7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.
Browse Prostatic Neoplasms studies →5 of the 24 studies testing piflufolastat in Prostatic Neoplasms are open now, in 1 country. Recruiting first, the newest first:
Akiva Mintz · Sites in United States
Ages 18–120 · Healthy volunteers
OHSU Knight Cancer Institute · Sites in United States
Ages 18+ · Men only
Brigham and Women's Hospital · Sites in United States
Ages 18+ · Men only
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Sites in United States
Ages 18–100 · Men only
National Cancer Institute (NCI) · Sites in United States
Ages 18–120 · Men only
By country, each count listing its studies:
piflufolastat: first EMA approval 2023. What it is approved for, and how studies give it, is on its page →
Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.
This study: 18 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
24 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 13 · Phase 3 4 · Phase 4 5
First in 2014; this study’s year is marked. 4 started in 2018.
This study's enrollment of 208 is above the median of 60 across 5,352 interventional studies indexed under Prostatic Neoplasms.
Median enrollment 55 across the 24 interventional studies. Of the 9 that completed or were terminated, 5 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 24 have an industry lead sponsor. The 10 most frequent:
This study is registered under Progenics Pharmaceuticals, Inc., one of the names counted as Lantheus Holdings, Inc.. Under that name alone:
Progenics Pharmaceuticals, Inc. is the lead sponsor of 8 studies on the registry; none are open to participants now.
22 studies in Prostatic Neoplasms by Lantheus Holdings, Inc.: 1 open now, 3 under way, 1 of them phase 3. Of 18 finished, 6 (33%) have results posted.
Among the 22 studies in Prostatic Neoplasms by Lantheus Holdings, Inc., this one is the 5th largest by enrollment of the 20 interventional ones that give a count, is the only one that started in 2018, is one of 2 in phase 3, and was the 18th registered.
Lantheus Holdings, Inc.’s Prostatic Neoplasms studies by the year they started, since 2008.
1 of the studies testing piflufolastat in Prostatic Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06099093Brigham and Women's HospitalPilot of 18F-DCFPyL-PSMA PET in mCRPC Patients Receiving 117Lu-Vipivotide Tetraxetan | 2026-12-01 |
Add it to your calendar (.ics) → With an account.
Among the 24 studies testing piflufolastat in Prostatic Neoplasms, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Lantheus Holdings, Inc.’s 22 in Prostatic Neoplasms:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study evaluates the diagnostic performance and safety of 18F-DCFPyL (PyL) PET/CT imaging in patients with suspected recurrence of prostate cancer who have negative or equivocal findings on conventional imaging.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Suspected recurrence of prostate cancer based on rising PSA after definitive therapy on the basis of:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
9 mCi (333 MBq) IV injection of 18F-DCFPyL
Drug: 18F-DCFPyL · Diagnostic Test: PET/CT Imaging
A single dose of 9 mCi (333 MBq) IV injection of 18F-DCFPyL
Also known as: PyL
PET/CT imaging will be acquired 1-2 hours post-PyL injection
Correct Localization Rate (CLR)
The Correct Localization Rate (CLR) will be defined as percentage of participants with a one-to-one correspondence between localization of at least one lesion identified on 18F-DCFPyL PET/CT imaging and the composite truth standard. Within 60 days following PyL PET/CT imaging, either biopsy/surgery, conventional imaging, or locoregional radiation therapy of the PyL-suspected lesion(s) will be performed.
Time frame: Within 60 days following 18F-DCFPyL PET/CT imaging.
Percentage of Participants With a Change in Intended Prostate Cancer Treatment Plans Due to 18F-DCFPyL PET/CT Imaging Results.
The change in the intended prostate cancer treatment plan will be based on Medical Management Questionnaires completed prior to and after 18F-DCFPyL PET/CT imaging.
Time frame: Pre 18F-DCFPyL PET/CT imaging and within 60 days following 18F-DCFPyL PET/CT imaging.
The Change From Pre- to Post- 18F-DCFPyl Dosing in Blood Pressure (Safety Outcome Measure)
The recorded values and their respective changes from the pre-dose values will be summarized using descriptive statistics.
Time frame: Measured at 2 intervals on the day of dosing; the first interval prior to receiving the 18F-DCFPyL dose and the second interval within 60 to 120 minutes after dosing.
The Change From Pre- to Post- 18F-DCFPyL Dosing in Heart Rate (Safety Outcome Measure)
The recorded values and their respective changes from the pre-dose values will be summarized using descriptive statistics.
Time frame: Measured at 2 intervals on the day of dosing; the first interval prior to receiving the 18F-DCFPyL dose and the second interval within 60 to 120 minutes after dosing.
Collection of Concomitant Medications (Safety Outcome Measure)
Medications will be coded using the WHO drug dictionary. The medications are summarized by ATC level 4 category and presented as number and percentage of participants. Results are presented where the percentage of participants within an ATC level 4 category is \>5.0.
Time frame: From the time of 18F-DCFPyL dosing to completion of the follow-up visit at 7 (±3) days after 18F-DCFPyL dosing.
Collection of Medical Procedures (Safety Outcome Measure)
Procedures will be coded using the same version of MedDRA as for medical history. Medical procedures will be displayed as a listing by participant.
Time frame: From the time of 18F-DCFPyL dosing to completion of the follow-up visit at 7 (±3) days after 18F-DCFPyL dosing.
| Milestone | 18F-DCFPyL Injection |
|---|---|
| Started | 208 |
| Completed | 195 |
| Not completed | 13 |
The Correct Localization Rate (CLR) will be defined as percentage of participants with a one-to-one correspondence between localization of at least one lesion identified on 18F-DCFPyL PET/CT imaging and the composite truth standard. Within 60 days following PyL PET/CT imaging, either biopsy/surgery, conventional imaging, or locoregional radiation therapy of the PyL-suspected lesion(s) will be performed.
| percentage of participants | 18F-DCFPyL Injection |
|---|---|
| Central Reader 1 | 85.6 (78.8 to 92.3) |
| Central Reader 2 | 87.0 (80.4 to 93.6) |
| Central Reader 3 | 84.8 (77.8 to 91.9) |
The change in the intended prostate cancer treatment plan will be based on Medical Management Questionnaires completed prior to and after 18F-DCFPyL PET/CT imaging.
| Participants | 18F-DCFPyL Injection |
|---|---|
| Percentage of Participants With a Change in Intended Prostate Cancer Treatment Plans Due to 18F-DCFPyL PET/CT Imaging Results. | 131 |
The recorded values and their respective changes from the pre-dose values will be summarized using descriptive statistics.
| mmHg | 18F-DCFPyL Injection |
|---|---|
| Systolic Blood Pressure: Baseline (actual) | 138.9 ± 18.61 |
| Systolic Blood Pressure: Post-dosing (actual) | 136.7 ± 17.15 |
| Systolic Blood Pressure: Change from Baseline | -2.2 ± 13.24 |
| Diastolic Blood Pressure: Baseline (actual) | 78.5 ± 10.18 |
| Diastolic Blood Pressure: Post-dosing (actual) | 77.3 ± 9.57 |
| Diastolic Blood Pressure: Change from Baseline | -1.2 ± 8.20 |
The recorded values and their respective changes from the pre-dose values will be summarized using descriptive statistics.
| bpm | 18F-DCFPyL Injection |
|---|---|
| Heart Rate: Baseline (actual) | 69.3 ± 12.75 |
| Heart Rate: Post-dosing (actual) | 65.1 ± 12.09 |
| Heart Rate: Change from Baseline | -4.3 ± 7.93 |
Medications will be coded using the WHO drug dictionary. The medications are summarized by ATC level 4 category and presented as number and percentage of participants. Results are presented where the percentage of participants within an ATC level 4 category is \>5.0.
| Participants | 18F-DCFPyL Injection |
|---|---|
| HMG COA REDUCTASE INHIBITORS | 103 |
| PLATELET AGGREGATION INHIBITORS (EXCLUDING HEPARIN) | 63 |
| ACE INHIBITORS, PLAIN | 36 |
| VITAMIN D AND ANALOGUES | 32 |
| ANGIOTENSIN II ANTAGONISTS, PLAIN | 31 |
| BETA BLOCKING AGENTS, SELECTIVE | 31 |
| DIHYDROPYRIDINE DERIVATIVES | 31 |
| PROTEIN PUMP INHIBITORS | 29 |
| DRUGS USED IN ERECTILE DYSFUNCTION | 23 |
| MULTIVITAMINS, PLAIN | 18 |
| BIGUANIDES | 17 |
| THIAZIDES, PLAIN | 16 |
| OTHER ANTIDEPRESSANTS | 15 |
| ALPHA-ADRENORECEPTOR ANTAGONISTS | 12 |
| PROPIONIC ACID DERIVATIVES | 12 |
| THYROID HORMONES | 11 |
| UNSPECIFIED HERBAL AND TRADITIONAL MEDICINE | 11 |
Procedures will be coded using the same version of MedDRA as for medical history. Medical procedures will be displayed as a listing by participant.
| Participants | 18F-DCFPyL Injection |
|---|---|
| Biopsy testes | 1 |
| Computerized tomogram | 1 |
| Nuclear magnetic resonance imaging | 1 |
| Ultrasound testes | 1 |
| Open reduction of fracture | 1 |
| Orchidectomy | 1 |
Collected over Treatment-emergent adverse events were collected after 18F-DCFPyL administration on Day 1 post-dose through the safety visit 7 (±3) days post-dosing.. Non-serious events are listed at a 1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 18F-DCFPyL Injection | 0/208 (0%) | 1/208 (0.5%) | 7/208 (3.4%) |
| Event | 18F-DCFPyL Injection |
|---|---|
| HypersensitivityImmune system disorders | 1/208 |
| HeadacheNervous system disorders | 1/208 |
| ParesthesiaNervous system disorders | 1/208 |
| Event | 18F-DCFPyL Injection |
|---|---|
| HeadacheNervous system disorders | 3/208 |
| FatigueGeneral disorders | 2/208 |
| HypertensionVascular disorders | 2/208 |
Safety population; all participants who received any amount of 18F-DCFPyL
| Age, Continuous(years) | 18F-DCFPyL Injection |
|---|---|
| Median | 68 (43 to 91) |
| Sex: Female, Male(Participants) | 18F-DCFPyL Injection |
|---|---|
| Female | 0 |
| Male | 208 |
| Race/Ethnicity, Customized(Participants) | 18F-DCFPyL Injection |
|---|---|
| Asian | 3 |
| Black or African American | 15 |
| White | 188 |
| Other, including not reported | 2 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Nov 2018 to primary completion in Aug 2019, 9 months.
Results were first posted in Jun 2021, 1 year 9 months after primary completion. A results delay was requested in Sep 2020.
Of 126 industry-sponsored phase 3 interventional studies under Prostatic Neoplasms, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 53. This study's 9 months is below that.
Counting every sponsor, half of 265 studies reached it within 57 months; a quarter within 31 and three quarters within 100.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Piflufolastat
Progenics Pharmaceuticals, Inc. →